What's New

The Gelfand lab demonstrates that apremilast reduces visceral and subcutaneous adiposity.

The Gelfand Lab investigates how to create the most effective implementation design for the CP3 Study, which aims to improve cardiovascular health in patients with psoriatic disease.

The Gelfand Lab publishes the first and largest mutli-center study of the epidemiology of generalized pustular psoriasis (GPP) and palmer planter pustulosis (PPP) in the US.

Selected Major Findings

The Gelfand Lab's research demonstrates that body surface area affected by psoriasis is an important predictor for major health outcomes. Check out results from the incidence health outcomes and psoriasis events (iHOPE) study:

The Gelfand Lab's research demonstrates an increased cardiovascular risk and an increased risk of diabetes, kidney disease and mortality in patients with psoriasis independent of traditional risk factors:

The Gelfand Lab determines the effect of psoriasis treatment on aortic vascular inflammation and biomarkers of inflammation, lipid and glucose metabolism:

The Gelfand Lab demonstrates the validity of electronic health data for studying psoriasis and psoriatic arthritis:

The Gelfand Lab's contributions to COVID research:

Educational Articles from Dr. Gelfand's Lab:

A full list of Dr. Gelfand's publications can be found on Google Scholar.